12th UMEM Critical Care Symposium Wednesday, May 21, 2025 Presentation by Dr. Daniel Boutsikaris

PEARLS & PITFALLS OF CRITICALLY ILL CIRRHOTIC PATIENT



DR. DANIEL BOUTSIKARIS, M.D. MEDICAL DIRECTOR OF MICU RUTGERS ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL NEW BRUNSWICK, NJ











Acute on Chronic Liver Failure


- The Asian Pacific Association for the Study of the Liver (APASL)
- THE EUROPEAN ASSOCIATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EASL-CLIF)
- THE NORTH AMERICAN CONSORTIUM FOR THE STUDY OF END-STAGE LIVER DISEASE (NACSELD)














































SBP TREATMENT		
TABLE 9 - Antibiotics for Infections in Recommended antibiotics in hospitalized (1) Spontaneous infections (peritonitis, bas Community acquired • Third-generation cephalosporin	patients with cirrhosis and infection	Ref: Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases
	 Meropenem if known to harbor MDR gram-negative organisms 	Revealed to the second

DON'T FORGET THE ALBUMIN	TABLE 4. IN-HOSPITAL MORTALITY ACCORDING TO VARIABLES WITH INDEPENDENT PREDICTIVE VALUE.*				
	Variable	CEFOTAXIME (N=63)		CEFOTAXIME PLUS ALBUMIN (N=63)	
		BUN <30 mg/dl	BUN ≥30 mg/dl	BUN <30 mg/dl	BUN ≥30 mg/dl
		no. c	of patients who	o died/total no	. (%)
	Bilirubin <4 mg/dl Prothrombin time ≥60% of control	0/13	3/6 (50)	0/10	1/10 (10)
	Prothrombin time <60% of control	0/7	2/8 (25)	0/14	2/5 (40)
	Bilirubin ≥4 mg/dl Prothrombin time ≥60% of control	1/3 (33)	1/5 (20)	0/0	0/1
	Prothrombin time <60% of control	4/12 (33)	7/9 (78)	0/16	3/7 (43)
	Total	5/35 (14)	13/28 (46)	0/40	6/23 (26)
The New England Journal of Medicine	*The cutoff points the overall group of pa (BUN) to millimoles p bilirubin to micromole	tients. To cor er liter, mult	iply by 0.357;	to convert th	rea nitrogen
August 1999					
olume 341 Number 6	(Mortality – 10% Con	<u>nbo vs. 2</u>	9% antik	piotics a	one, P=0


RUTGERS HEALTH Robert Wood Johnson Medical School

EARLY SEPSIS IS HARD TO DIAGNOSIS

- 1) Impaired Lactate Clearance
- 2) Vasodilator Production from portal hypertension lower MAP
- 3) Alcohol Associated hepatitis increases WBC and other markers of inflammation
- 4) Relative Adrenal Insufficiency is common in Cirrhotic patients
- 5) Fever is often absent

Consider infection esp when a patient with cirrhosis deteriorates, particularly with encephalopathy, AKI, and/or jaundice

- PT WITH ACLF WHO SURVIVE INFECTION -> 45% WILL HAVE ANOTHER INFECTION WITHIN 6 MONTHS.
- 1/3RD OF HOSPITALIZED CIRRHOTIC PATIENTS WILL HAVE BACTERIAL INFECTIONS (35% ARE MDRO).





RUTGERS HEALTH Robert Wood Johnson Medical School


ALTERED MENTAL STATUS


- HEPATIC ENCEPHALOPATHY -> <u>DIAGNOSIS OF EXCLUSION</u>
 - DRUG RELATED
 - INFECTIONS
 - DIABETIC KETOACIDOSIS/HYPEROSMOLAR HYPERKETOTIC STATE
 - ELECTROLYTE DISORDERS (HYPONATREMIA)
 - INTRACRANIAL PATHOLOGY SUCH AS BLEED
 - NONEPILEPTIC SEIZURES
 - Some can coexist with HE


2	—
2	Э
	-















WHAT ABOUT FFP ?


• FRESH FROZEN PLASMA FRESH FROZEN PLASMA (APPROXIMATELY 250 ML/U AND DOSED AT 10 ML/KG) <u>IS NOT RECOMMENDED</u> TO CORRECT ANY COAGULATION FACTOR DEFICIENCY. AFTER A HIGH VOLUME IS INFUSED, THERE IS A SUBSTANTIAL INCREASE IN PORTAL PRESSURE.

	All patients (n = 244)	Received FFP transfusion (n $=$ 100)	Did not receive FFP transfusion ($n = 144$)	Unadjusted OR (95% CI)	Adjusted OR (95% CI) ^a
Mortality at 42 d, n (%)	47 (19.3)	37 (37.0)	10 (6.9)	7.87 (3.68-16.83)	9.41 (3.71-23.90)
Failure to control bleeding at 5 d, n (%)	20 (8.2)	14 (14.0)	6 (4.2)	3.74 (1.39-10.11)	3.87 (1.28-11.70)
Length of stay >7 d, n (%)	85 (34.8)	51 (51.0)	34 (23.6)	3.37 (1.94-5.83)	1.88 (1.03-3.42)


Mohanty A, Kapuria D, Canakis A, et al. Fresh frozen plasma transfusion in acute variceal haemorrhage: Results from a multicenter cohort study. Liver Int. 2021;41:1901–1908.










HEMOSTASIS:	
Gastroenterology 2019;157:34–43 <u>BEST PRACTICE ADVICE 1:</u> Global tests of clot formation, such as rotational thromboelastometry, thromboelas- tography, sonorheometry, and thrombin generation, may even- tually have a role in the evaluation of clotting in patients with cirrhosis, but currently lack validated target levels.	
TABLE 9 Future research directions for the management of critically ill patients with cirrhosis and/or ACLF	
Coagulopathy Utilization of viscoelastic testing (TEG/ROTEM) in larger populations of critically ill patients with cirrhosis Hepatology. 2024;79:1180–1211 AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis	RUTGERS HEATTH Robert Wood Johnson Medical School







<text><text><text><text>



RUTGERS HEALTH Robert Wood Johnson Medical School

RECAP:

- Decompensated Cirrhotic pt's have a high 1-Year mortality
- INFECTION IS ONE OF THE MOST COMMON CAUSES OF DEATH BUT DIFFICULT TO DIAGNOSIS
- SBP is a Cellular Diagnosis Inoculate a Blood Culture Bottle to increase yield
- CONSIDER POLYETHYLENE GLYCOL FOR TREATMENT OF HEPATIC ENCEPHALOPATHY
- Don't use FFP to target an Arbitrary INR
- CONSIDER TEG/ROTEM TO GUIDE TRANSFUSION
- ADRENAL INSUFFICIENCY MAY BE MORE COMMON IN THIS POPULATION

